First AD

Second AD

Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.

Compounding Impact of TAS-102 and Bevacizumab in mCRC Treatment

Colorectal Cancer

 Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Expert Perspectives & Insights into the Evolving Treatment of Refractory Metastatic Colorectal Cancer

Peer Exchange

City of Hope

Cancer Centers

Partner

Moffitt Cancer Center

Baylor Scott & White Charles A. Sammons Cancer Center 

Allina Health System

Overview of Current mCRC Treatment Landscape

Evaluating 3L Treatment Landscape Evolution

Fruquintinib MoA and Toxicity Profile Overview

FRESCO-2 Study Highlights

Dose Modifications and Tolerability Associated with mCRC Treatment Regimens

Utilizing RWE to Derive Optimal Treatment Strategy for Refractory mCRC

Consideration for Fruquintinib Dosing and Titration

Fatigue Associated with Bevacizumab, Fruquintinib, TAS-102 Therapies

Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment

Considerations for Platinum-based Therapy

Treatment Sequencing for Refractory mCRC and SUNLIGHT Study Analysis

Real-World Data Surrounding Sequencing Strategies for Refractory mCRC

Data Surrounding Treatment for MSI-high Patients from ASCO 2024

Unmet Needs Surrounding mCRC Treatment

Anticipating Key Studies and Pipeline Treatments in mCRC Landscape